Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole in NOA and Severe Oligozoospermia
NCT02900105Phase 3Completed
- Sponsor
- KK Women's and Children's Hospital
- Start
- Feb 2015
- Primary completion
- Mar 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of letrozole in non obstructive azoospermia (NOA) and oligozoospermia, sponsored by KK Women's and Children's Hospital. Primary endpoints: Sperm density at 4 months and Sperm motility at 4 months. Started Feb 2015; status: completed.
02
Drugs
letrozole
03
Conditions
non obstructive azoospermia (NOA)oligozoospermia
Beyond the preview
Go deeper on NCT02900105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02900105.